Clearside Biomedical Azioni (NASDAQ: CLSD)

Clearside Biomedical (NASDAQ:CLSD) Azioni

Clearside Biomedical

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical Inc

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=enUbUY5_QZwJp_8KN6336lY1IB1ulJx95BWFgrcVl5jC3L4RVRNvTx6gaBSkE_ynFCK_In3ODIR5MaPchbZ6Fg==">LifeMD, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>), a leading provider of virtual primary care services, today announced expanded acceptance of insurance to Medicare beneficiaries for qualifying care. Initially available to more than 21 million Medicare Part B beneficiaries in 26 states, the company expects to expand access to medically necessary services for more than 60 million Medicare beneficiaries nationwide, with access to qualifying services across 49 states anticipated by the end of the second quarter.

News

LFMD

Lifemd Announces Expanded Acceptance Of Insurance To Medicare Beneficiaries For Qualifying Care

Biotech

General

ALEC

Alector Completes Enrollment In PROGRESS-AD Phase 2 Clinical Trial If AL101/GSK4527226 For Individuals With Early Alzheimer's Disease

Scrambling to submit your taxes even after the April 15 deadline? <a href="https://www.benzinga.com/money/how-to-file-your-own-taxes">Filing for an extension</a> can be a lifesaver if you're juggling personal obligations or wrestling with intricate returns. Rather than rushing, you can secure six extra months to organize your finances and file without penalty.
<h4 class="wp-block-heading">Why Bother With An Extension?</h4>
Not everyone can meet the IRS's recommendation to file early. Unexpected life events, delayed documents, or a complicated tax situation might slow you down. An extension buys you breathing room until October 15, letting you gather all your paperwork without incurring a "failure to file" penalty.
<h4 class="wp-block-heading">Who Gets More Time Automatically?</h4>
Certain exceptions already exist according to the IRS website. If you're on active military duty in a <a href="https://www.irs.gov/individuals/military/combat-zones">combat zone</a>, you get 180 days after leaving that area to file. Americans <a href="https://www.irs.gov/individuals/international-taxpayers/us-citizens-and-resident-aliens-abroad-automatic-2-month-extension-of-time-to-file">living abroad</a> or stationed overseas also receive an automatic two-month extension. Meanwhile, residents in states <a href="https://www.irs.gov/newsroom/tax-relief-in-disaster-situations">affected by natural disasters</a> can receive extra filing time, sometimes until November 3.
See also: <a href="https://www.benzinga.com/25/04/44855064/trump-administration-asks-irs-to-revoke-harvards-tax-exempt-status-after-president-accuses-ivy-league-university-of-pushing-sickness">Trump Administration Asks IRS To Revoke Harvard&#8217;s Tax-Exempt Status After President Accuses Ivy League University Of Pushing &#8216;Sickness&#8217;</a>
<h4 class="wp-block-heading">How To File For An Extension Online?</h4>
To request an extension, use the IRS's online payment system: Simply check the box indicating you need extra time. Alternatively, you can e-file <a href="https://www.irs.gov/forms-pubs/about-form-4868">Form 4868</a> (Application for Automatic Extension of Time to File U.S. Individual Income Tax Return), which just asks for your basic personal information. Both options give you a quick, digital route to notification-free breathing space.
<h4 class="wp-block-heading">Your Payment Will Still Be Due</h4>
An extension shifts your paperwork deadline, not your tax bill due date. If you owe money, estimate the total, then pay by April 15 to dodge the "failure to pay" penalty. Missing the payment deadline could saddle you with monthly fees, ultimately capping at <a href="https://www.irs.gov/newsroom/taxpayers-should-file-their-tax-return-on-time-to-avoid-costly-interest-and-penalty-fees">25% of your unpaid taxes</a>.
<h4 class="wp-block-heading">Can't Pay Your Tax Bill?</h4>
If you're short on cash, the IRS offers both short-term and long-term <a href="https://www.irs.gov/payments/payment-plans-installment-agreements">payment plans</a>. You can apply online, and if you can show "reasonable cause" for late or partial payments, you might avoid some penalties. The main thing is to communicate with the IRS early, so you stay in good standing.
Read next: <a href="https://www.benzinga.com/government/regulations/25/04/44731006/when-are-your-deposits-flagged-understanding-how-and-why-banks-report-transactions-to-the-irs">When Are Your Deposits Flagged? Understanding How And Why Banks Report Transactions To The IRS</a>

Financing

Legal

Personal Finance

Running Late On Your Return? How To Secure A No-Penalty Tax Extension

Management

Utz Appoints William J. Kelley Jr. As CFO, Effective May 1, 2025

Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications
NEW YORK, April 17, 2025 /PRNewswire/ --&nbsp;Hoth Therapeutics, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today announced it has been granted a key patent by the Japan Patent Office (JPO), expanding its global intellectual property portfolio in RNA-based cancer therapeutics.
The newly issued patent secures broad claims covering antisense oligomers that target the&nbsp;KIT&nbsp;gene — a clinically validated oncogene associated with gastrointestinal stromal tumors (GIST), leukemia, mastocytosis, and other cancers. These oligomers are designed to alter pre-mRNA splicing or reduce KIT protein expression, offering a highly targeted therapeutic mechanism.
"This patent significantly strengthens Hoth's position in the RNA therapeutics space and marks a major milestone in our global strategy,"&nbsp;said&nbsp;Robb Knie, CEO of Hoth Therapeutics.&nbsp;"Targeting the KIT pathway with antisense technology represents a precision-driven approach that holds immense potential in oncology and beyond. This grant provides strong validation and global momentum as we continue advancing our RNA platform toward the clinic."

HOTH

Hoth Therapeutics Granted Japanese Patent Expanding Global Intellectual Property Portfolio In RNA-based Cancer Therapeutics

Wells Fargo initiates coverage on Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Equal-Weight rating and announces Price Target of $4.

Price Target

Initiation

Analyst Ratings

RLAY

Wells Fargo Initiates Coverage On Relay Therapeutics with Equal-Weight Rating, Announces Price Target of $4

Contracts

KTOS

Kratos Receives ~$30M Sole Source Air Defense System Hardware Production Award

JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) CEO Jamie Dimon offered his insights on global trade and U.S.-China relations amid escalating tariff tensions.
What Happened: In a recent interview <a href="https://www.ft.com/video/1315e028-8cbb-40fa-b9eb-4ba2df57edfc">with</a> the Financial Times, Dimon emphasized the importance of respectful and consistent dialogue between the U.S. and China to ease trade tensions. While acknowledging China&#8217;s significant economic growth and success, he also highlighted widespread global concerns over its trade practices and regional influence.
Dimon, referring to complaints about China flooding global markets with excess capacity, said, &#8220;They&nbsp;are scaring Japan, Korea, Indonesia,&nbsp;Vietnam, India.&#8221; He urged Chinese authorities to be receptive to addressing these concerns.
The JPMorgan Chase CEO argued against total economic decoupling from China, stating it&nbsp;is neither desirable nor necessary.&nbsp;He said that while it is &#8220;definitely possible&#8221;&#8230;&#8221;I don&#8217;t think that should be the objective.&#8221; He proposed that the U.S. should be self-dependent and collaborate with allies like Europe, the U.K., Japan, Korea, Australia, Philippines to jointly negotiate for equitable trade agreements. 
When asked if President Donald Trump should call Chinese President Xi Jinping, Dimon did not answer directly but said, &#8220;I think adults should talk to each other and listen to each other and acknowledge when the other person is right, or at least has a good point.&#8221; The CEO expressed optimism that the engagement between both countries would happen in the future. &#8220;You start with a phone call,&#8221; said Dimon. 
Despite apprehensions about a recent dip in the U.S. dollar, Dimon expressed&nbsp;confidence in the U.S. economy,&nbsp;highlighting&nbsp;its rule of law, innovation,&nbsp;and military power. He cautioned against taking America&#8217;s position for granted, stating, &#8220;America&nbsp;First is OK, but not&nbsp;America Alone.&#8221; The JPMorgan CEO stated that fragmentation in the Western world is a &#8216;bad idea&#8217;. &#8220;We don&#8217;t read a book in 40 years: &#8216;How the West was Lost&#8217;,&#8221; stated the JPMorgan CEO. 
Jamie Dimon stated that though he doesn&#8217;t agree with everything that the Trump administration does, he hopes that Treasury Secretary Scott Bessent would lead the trade deals well. 
SEE ALSO:&nbsp;<a href="https://benzinga.com/tech/25/04/44857520/bill-gates-says-his-kids-and-grandkids-will-live-in-a-very-changed-world-as-ai-puts-an-end-to-shortage-of-teachers-and-doctors" target="_blank" rel="noreferrer noopener">Bill Gates Says His Kids And Grandkids Will Live In A &#8216;Very Changed World&#8217; As AI Puts An End To Shortage Of Teachers And Doctors &#8211; Benzinga</a>
Why It Matters: This isn&#8217;t the first time Dimon has expressed his views on trade tensions. Earlier in April, he cautioned that President Donald Trump&#8216;s tariffs could <a href="https://www.benzinga.com/25/04/44665530/jamie-dimon-once-a-tariff-supporter-warns-trumps-new-policy-could-slow-us-growth-fuel-inflation-the-quicker-the-issue-is-resolved-the-better">trigger inflation</a> and slow down the U.S. economy. He warned of potential short-term effects, including inflationary impacts on both imported and domestic goods.
Later in the same month, during JPMorgan&#8217;s first-quarter earnings call, Dimon offered more insights on the possible effects of these tariffs on businesses and the economy. He spoke with JPMorgan economist Michael Farley, who updated the bank's most current forecast, which calls for 50/50 <a href="https://www.benzinga.com/news/management/25/04/44774273/jpmorgan-ceo-jamie-dimon-expects-sp-500-growth-forecast-to-be-cut">chances of a recession</a> due to the ongoing global trade tensions. 
Meanwhile, the U.S. tariffs on China have risen to 245% while President Donald Trump awaits negotiations talks from Chinese President Xi Jinping.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/management/25/04/44846882/big-bank-ceos-weigh-in-on-trumps-turbulent-economy" target="_blank" rel="noreferrer noopener">Big Bank CEOs Weigh In On Trump&#8217;s Turbulent Economy</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

'America First Is OK, But Not America Alone,' Says Jamie Dimon As He Calls For US-China Engagement Amid Trade Tensions— 'Start With A Phone Call'

MARLBOROUGH, Mass., April 17, 2025 /PRNewswire/ -- ConnectM Technology Solutions, Inc. (Nasdaq:&nbsp;CNTM) ("ConnectM" or the "Company"), a high-growth technology company on the leading edge of the energy economy, today announced that the Company has retired an additional&nbsp;$9 million&nbsp;of debt since March 31, 2025. Since going public on&nbsp;July 15, 2024, ConnectM has eliminated&nbsp;$40 million&nbsp;in liabilities, bringing total outstanding debt to less than&nbsp;$8.0 million.

CNTM

ConnectM Retires $9M Debt In April And Reduces Annual Interest Expense By 90%

KAPA

Kairos Pharma Ltd. Announces $876,000 Department Of Defense Grant To Support Its Study Of ENV105 To Prevent Drug Resistance In Lung Cancer

Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) is the world&#8217;s second-largest company, with a market capitalization of $2.89 trillion. It develops and supports software, services, devices and solutions worldwide.
It will report its Q3 2025 earnings on April 30. Wall Street analysts expect the company to post EPS of $3.17, up from $2.94 in the year-ago period. According to data from Benzinga Pro, quarterly revenue is expected to be $69.91 billion, up from $61.86 billion a year earlier.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
The 52-week range of Microsoft stock price was $344.79 to $468.35.
Microsoft's dividend yield is 0.87%. It paid $3.32 per share in dividends during the last 12 months.
<h2 class="wp-block-heading">The Latest On Microsoft</h2>
On Jan. 29, the company announced its Q2 2025 earnings, posting quarterly GAAP earnings of $3.23 per share, beating the $3.11 consensus estimate, as reported by <a href="https://www.benzinga.com/news/earnings/25/01/43320124/microsoft-shares-slide-after-q2-results-cloud-revenue-misses-expectations-details">Benzinga</a>. Quarterly revenue clocked in at $69.6 billion, beating the $68.78 billion analyst consensus estimate.
Last week, Wedbush analyst Daniel Ives slammed the ongoing "tariff game of poker" for fueling significant near-term uncertainty among tech companies, including Microsoft.
Ives said that despite President Donald Trump‘s 90-day pause on tariffs for certain countries, companies that are reliant on Chinese supply chains or cost inputs are still vulnerable.
Ives estimates that around 10% to 15%—possibly a conservative figure—of U.S. cloud and AI initiatives currently being tracked could be delayed or slowed during this period of heightened uncertainty. Microsoft is expected to be "front and center" of this economic climate, he adds.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
<h2 class="wp-block-heading">How Can You Earn $100 Per Month As A Microsoft Investor?</h2>
If you want to make $100 per month — $1,200 annually — from Microsoft dividends, your investment value needs to be approximately $137,931, which is around 355 shares at $388.45 each.&nbsp;
Understanding the dividend yield calculations: When making an estimate, you need two key variables — the desired annual income ($1,200) and the dividend yield (0.87% in this case). So, $1,200 / 0.0087 = $137,931 to generate an income of $100 per month.
You can calculate the dividend yield by dividing the annual dividend payments by the current price of the stock.
The dividend yield can change over time. This is the outcome of fluctuating stock prices and dividend payments on a rolling basis.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
For instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40).
In summary, income-focused investors may find Microsoft stock an attractive option for making a steady income of $100 per month by owning 355 shares of stock. There may be more upside to come as investors benefit from the company's consistent dividend hikes. Microsoft has raised its dividend consecutively for the last 19 years.&nbsp;
Check this <a href="https://www.benzinga.com/25/04/44732057/how-brookfield-infrastructure-archer-daniels-midland-and-robert-half-can-put-cash-in-your-pocket">article by Benzinga</a> for three more stocks offering high dividend yields.
Read Next:
<ul>
<li>With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

MSFT

How Much Would It Take To Earn $100 A Month From Microsoft Stock

CRH Names Nancy Buese CFO, Effective May 12, 2025

11 analysts have expressed a variety of opinions on Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $94.82, a high estimate of $124.00, and a low estimate of $73.00. This current average has decreased by 2.16% from the previous average price target of $96.91. 
<img src="https://www.benzinga.com/files/images/story/2025/1744891351_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Docusign's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Josh Baer &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $92.00&#x7C;$97.00 &#x7C; 
&#x7C;Brent Thill &#x7C;Jefferies &#x7C;Lowers &#x7C;Buy &#x7C; $105.00&#x7C;$115.00 &#x7C; 
&#x7C;Tyler Radke &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $115.00&#x7C;$113.00 &#x7C; 
&#x7C;Rishi Jaluria &#x7C;RBC Capital &#x7C;Maintains &#x7C;Sector Perform &#x7C; $90.00&#x7C;$90.00 &#x7C; 
&#x7C;Patrick Walravens &#x7C;Citizens Capital Markets&#x7C;Maintains &#x7C;Market Outperform&#x7C; $124.00&#x7C;$124.00 &#x7C; 
&#x7C;Mark Murphy &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $81.00&#x7C;$75.00 &#x7C; 
&#x7C;Karl Keirstead &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $90.00&#x7C;$100.00 &#x7C; 
&#x7C;Michael Turrin &#x7C;Wells Fargo &#x7C;Raises &#x7C;Underweight &#x7C; $73.00&#x7C;$70.00 &#x7C; 
&#x7C;Daniel Ives &#x7C;Wedbush &#x7C;Maintains &#x7C;Neutral &#x7C; $100.00&#x7C;$100.00 &#x7C; 
&#x7C;Brad Sills &#x7C;B of A Securities &#x7C;Lowers &#x7C;Neutral &#x7C; $98.00&#x7C;$112.00 &#x7C; 
&#x7C;Mark Murphy &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $75.00&#x7C;$70.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Docusign. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Docusign compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Docusign's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Docusign's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DOCU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Docusign analyst ratings.</a>
<h2>All You Need to Know About Docusign</h2>
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.
<h3>A Deep Dive into Docusign's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Docusign's revenue growth over a period of 3M has been noteworthy. As of 31 January, 2025, the company achieved a revenue growth rate of approximately 8.97%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.76%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Docusign's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 4.18%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Docusign's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 2.15%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.06.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DOCU

Beyond The Numbers: 11 Analysts Discuss Docusign Stock

First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.67, with a high estimate of $25.00 and a low estimate of $20.00. This current average represents a 2.16% decrease from the previous average price target of $23.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1744891334_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive First Horizon is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ebrahim Poonawala &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $24.00&#x7C;$23.00 &#x7C; 
&#x7C;Timur Braziler &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $20.00&#x7C;$22.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $23.00&#x7C;$25.00 &#x7C; 
&#x7C;David George &#x7C;Baird &#x7C;Maintains &#x7C;Outperform &#x7C; $22.00&#x7C;$22.00 &#x7C; 
&#x7C;Michael Rose &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $22.00&#x7C;$23.00 &#x7C; 
&#x7C;Ben Gerlinger &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $25.00&#x7C;$24.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to First Horizon. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of First Horizon compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of First Horizon's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into First Horizon's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FHN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on First Horizon analyst ratings.</a>
<h2>All You Need to Know About First Horizon</h2>
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer &amp; Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer &amp; Wealth. The Commercial, Consumer &amp; Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
<h3>Unraveling the Financial Story of First Horizon</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining First Horizon's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -9.52% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 22.33%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): First Horizon's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.85%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): First Horizon's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.19%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: First Horizon's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.27.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About First Horizon Stock

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% decrease, the current average has fallen from the previous average price target of $912.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1744891323_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Regeneron Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Tim Anderson &#x7C;B of A Securities &#x7C;Lowers &#x7C;Underperform &#x7C; $547.00&#x7C;$575.00 &#x7C; 
&#x7C;Salveen Richter &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $917.00&#x7C;$1019.00 &#x7C; 
&#x7C;Chris Schott &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $1000.00&#x7C;$1100.00 &#x7C; 
&#x7C;Brian Skorney &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $759.00&#x7C;$940.00 &#x7C; 
&#x7C;David Risinger &#x7C;Leerink Partners &#x7C;Raises &#x7C;Outperform &#x7C; $834.00&#x7C;$762.00 &#x7C; 
&#x7C;Geoff Meacham &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $750.00&#x7C;$795.00 &#x7C; 
&#x7C;Christopher Raymond &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $1013.00&#x7C;$1195.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Regeneron Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Regeneron Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/REGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Regeneron Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Regeneron Pharmaceuticals</h2>
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
<h3>Regeneron Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Regeneron Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.33% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Regeneron Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 24.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.13% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Regeneron Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.44% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

REGN

Assessing Regeneron Pharmaceuticals: Insights From 7 Financial Analysts

Lost Creek Production
During 2025 Q1, we dried and packaged 83,066 pounds and shipped 106,301 pounds U3O8. At quarter end, our in-process inventory at Lost Creek was approximately 29,700 pounds, our drummed inventory at Lost Creek was 10,772 pounds, and our finished inventory at the conversion facility was 368,540 pounds. Our next shipment of product is scheduled for next week and we currently have 57 drums of product on the ground at Lost Creek.
We are pleased to report that the wellfield flow rate has increased by 44% since the beginning of March 2025 and is now routinely over 2,700 gallons per minute. Additional flow increases are expected throughout the summer as our current fleet of 19 contract drill rigs and Company construction staff bring on additional header houses and enhance flow in existing wells through routine maintenance and improvements. Head grade remains on target and our annualized production rate over the past week averaged over 400,000 pounds and remains on a positive trend. For context, our 2025 delivery commitment to our customers is 440,000 pounds of U3O8 and the repayment of a 250,000-pound U3O8 loan in the form of physical pounds, although repayment of this loan may be deferred upon agreement with the lender. We expect production rates to steadily increase throughout the summer.
The recovery rate in the processing plant has reached design levels as management of the elution circuit has improved, resulting in tail grade on the ion exchange columns commonly being less than three milligrams per liter. The elution and precipitation circuits are now functioning as designed. Both filter presses are operational, and we plan to upgrade the auger in each of the presses in early May, which should further improve throughput. Both rotary vacuum dryers are now operating and performing as designed.
Our safety performance has improved over the past several months with no recordable injury or illness incidents occurring in 2025. Implementation of a behavioral based safety program to proactively address and track potential safety issues has resulted in an improved safety culture and has increased employee participation in Company safety initiatives.
The recent improvements in performance and safety are attributable to several factors of which we believe the most important are growing employee skills and confidence and achieving higher employee retention rates. Our increased number of drill rigs together with mild winter conditions have also contributed to increased output.
Our objectives for Lost Creek for the remainder of 2025 are to continue to safely ramp up the wellfield flow rate and improve plant efficiencies by focusing on training, employee retention, and improved maintenance.
Shirley Basin Construction
Construction at our fully permitted Shirley Basin Project is on target and we continue to estimate mine startup by early 2026. We have hired many of our senior site management and 10 construction staff, who are already directly involved with facility construction. Training of new staff is ongoing, including certain training being conducted at Lost Creek. We have hired several additional professional staff who will join the Shirley Basin team in Q2. Recruiting for operational staff, including remaining managers, will be ongoing through the summer.
To date, the following construction activities have been completed:
Upgraded the existing road to an all-weather surface;
Installed and completed ~125 monitor wells for Mine Unit 1;
Refurbished the existing warehouse, construction bay and maintenance bay. We originally planned to construct new buildings but saved several million dollars by refurbishing existing buildings;
Installed and furnished modular offices for these buildings;
Installed power between the Company substation and the site for the satellite plant enclosure;
Initiated dirt work for the satellite plant foundation;
Installed communications and security systems;
Installed the septic system for the satellite plant enclosure; and
Advanced the construction of the ion exchange vessels, which is well underway in Casper with delivery expected this fall.
Before we initiate production at Shirley Basin, the Wyoming Uranium Recovery Program will perform a pre-operations inspection. To improve the efficiency of the inspection and operational approvals, we have begun to assemble Standard Operating Procedures and permitting documents for agency review.
In 2025, we plan to:
Complete the upgrade the Company-owned electrical substation;
Install the first header house in Mine Unit 1. Two drill rigs were mobilized to the project on April 14 from Lost Creek. We plan to add four more rigs in Q2. Relatively few drill rigs are required for Shirley Basin because dense historic drilling largely diminishes the need for additional exploration or delineation drilling;
Build the relatively small satellite plant enclosure, which will house the ion exchange and wastewater management systems;
Construct additional header houses in our Casper shop;
Install and furnish modular offices for the satellite plant enclosure; and
Install two evaporation ponds.
We are excited to bring Shirley Basin, a prolific historic uranium district and the birthplace of in situ uranium mining in 1963, back into production.
Finally, we want to briefly mention President Trump's recent Executive Order that directed the U.S. Department of Commerce to start a national security probe under Section 232 of the Trade Expansion Act of 1962 into the impact of imports of critical minerals and uranium. The investigation is ordered to be completed within 180 days when a final report with recommendations is submitted to the President. The impact of the investigation and subsequent corrective actions, if any, are unknown at this time but could have a positive impact on Ur-Energy as one of the largest domestic uranium producers in the U.S.

Ur-Energy Provides Production and Construction Updates For 2025 Q1 Including Drying And Packaging 83,066 Pounds And Shipping 106,301 Pounds At Lost Creek Facility

Wells Fargo analyst Eva Fortea Verdejo initiates coverage on Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) with a Underweight rating and announces Price Target of $8.

BCAX

Wells Fargo Initiates Coverage On Bicara Therapeutics with Underweight Rating, Announces Price Target of $8

H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) underwent analysis by 3 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $60.67, a high estimate of $72.00, and a low estimate of $50.00. A decline of 6.66% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1744891297_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of H.B. Fuller by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ghansham Panjabi &#x7C;Baird &#x7C;Maintains &#x7C;Outperform &#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Jeffrey Zekauskas &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $50.00&#x7C;$60.00 &#x7C; 
&#x7C;David Begleiter &#x7C;Deutsche Bank &#x7C;Lowers &#x7C;Buy &#x7C; $72.00&#x7C;$75.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to H.B. Fuller. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of H.B. Fuller compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for H.B. Fuller's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of H.B. Fuller's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FUL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on H.B. Fuller analyst ratings.</a>
<h2>About H.B. Fuller</h2>
H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
<h3>H.B. Fuller's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: H.B. Fuller's revenue growth over a period of 3M has faced challenges. As of 28 February, 2025, the company experienced a revenue decline of approximately -2.68%. This indicates a decrease in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: H.B. Fuller's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.68%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): H.B. Fuller's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.73%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): H.B. Fuller's ROA stands out, surpassing industry averages. With an impressive ROA of 0.27%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.23, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into H.B. Fuller Stock: Analyst Perspectives (3 Ratings)

In the latest quarter, 11 analysts provided ratings for Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $707.0, a high estimate of $785.00, and a low estimate of $600.00. A decline of 2.26% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1744891285_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Intuit's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C; Allan Verkhovski &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Outperform&#x7C; $700.00&#x7C;$600.00 &#x7C; 
&#x7C;Keith Weiss &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $720.00&#x7C;$730.00 &#x7C; 
&#x7C;Scott Schneeberger &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $642.00&#x7C;$722.00 &#x7C; 
&#x7C;Brent Thill &#x7C;Jefferies &#x7C;Lowers &#x7C;Buy &#x7C; $735.00&#x7C;$800.00 &#x7C; 
&#x7C;Mark Murphy &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $660.00&#x7C;$640.00 &#x7C; 
&#x7C;Siti Panigrahi &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $765.00&#x7C;$750.00 &#x7C; 
&#x7C; Allan Verkhovski &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Perform &#x7C; $600.00&#x7C;$700.00 &#x7C; 
&#x7C;Steven Enders &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $726.00&#x7C;$760.00 &#x7C; 
&#x7C;Daniel Jester &#x7C;BMO Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $714.00&#x7C;$760.00 &#x7C; 
&#x7C;Keith Weiss &#x7C;Morgan Stanley &#x7C;Maintains &#x7C;Overweight &#x7C; $730.00&#x7C;$730.00 &#x7C; 
&#x7C;Arvind Ramnani &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $785.00&#x7C;$765.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Intuit. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Intuit compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Intuit's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intuit's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INTU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intuit analyst ratings.</a>
<h2>All You Need to Know About Intuit</h2>
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small business accounting and do-it-yourself tax filing in the US.
<h3>Intuit's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Intuit's revenue growth over a period of 3M has been noteworthy. As of 31 January, 2025, the company achieved a revenue growth rate of approximately 17.04%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Intuit's net margin is impressive, surpassing industry averages. With a net margin of 11.88%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Intuit's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.61%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Intuit's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.45%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Intuit's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.38.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTU

Intuit Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)

Throughout the last three months, 12 analysts have evaluated Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $11.92, along with a high estimate of $18.00 and a low estimate of $6.00. Highlighting a 22.4% decrease, the current average has fallen from the previous average price target of $15.36. 
<img src="https://www.benzinga.com/files/images/story/2025/1744891273_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Sunrun among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;---------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Vikram Bagri &#x7C;Citigroup &#x7C;Announces &#x7C;Neutral &#x7C; $7.00&#x7C;- &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $6.00&#x7C;$9.00 &#x7C; 
&#x7C;Biju Perincheril &#x7C;Susquehanna &#x7C;Lowers &#x7C;Positive &#x7C; $10.00&#x7C;$13.00 &#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;Jefferies &#x7C;Lowers &#x7C;Hold &#x7C; $8.00&#x7C;$14.00 &#x7C; 
&#x7C;Jon Windham &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $15.00&#x7C;$17.00 &#x7C; 
&#x7C;Christopher Dendrinos&#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $14.00&#x7C;$17.00 &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $9.00&#x7C;$12.00 &#x7C; 
&#x7C;Brian Lee &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $15.00&#x7C;$17.00 &#x7C; 
&#x7C;Ameet Thakkar &#x7C;BMO Capital &#x7C;Lowers &#x7C;Market Perform &#x7C; $9.00&#x7C;$11.00 &#x7C; 
&#x7C;Christine Cho &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $15.00&#x7C;$18.00 &#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;Jefferies &#x7C;Lowers &#x7C;Buy &#x7C; $17.00&#x7C;$19.00 &#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $18.00&#x7C;$22.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sunrun. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sunrun compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Sunrun's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Sunrun's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RUN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sunrun analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Sunrun</h2>
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed either by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
<h3>Key Indicators: Sunrun's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Sunrun displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 0.37%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Sunrun's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -542.66%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Sunrun's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -71.85%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Sunrun's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -13.4%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 5.1, Sunrun faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Sunrun Stock

Press Releases

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

Health Care

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD  and Suprachoroidal Delivery Platform Highlighted at the  2025 Wet AMD & Diabetic Eye Disease Summit

Comments

Clearside Biomedical

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO